臨床試験のために PNKP阻害剤の生産量を 1,560gと2kgまで拡大した. Onco-Innovations scaled up PNKP inhibitor production to 1,560 grams and 2 kg for clinical trials.

Onco-Innovationsは,Dalton Pharma Servicesと協力してPNKP阻害剤の製造拡大を進めており,前駆体A83の1560グラム合成を達成し,活性薬剤成分A83B4C63の2キログラムの非GMP生産を開始しました. Onco-Innovations has advanced the manufacturing scale-up of its PNKP inhibitor in collaboration with Dalton Pharma Services, achieving a 1,560-gram synthesis of precursor A83 and initiating a 2 kg non-GMP production of the active pharmaceutical ingredient A83B4C63. この作業は,INDを有効にする研究と将来の臨床試験を支援し,トロントの施設でのプロセス堅実性と製造準備を強化します. This work supports IND-enabling studies and future clinical trials, strengthening process robustness and manufacturing readiness at a Toronto facility. 同社はまた,企業の知名度のためにMCSとの市場コミュニケーションの関与を拡大しました. The company also extended its market communications engagement with MCS for corporate visibility.